Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico
Results show that romosozumab/ denosumab produces greater health benefits at a lower total cost than teriparatide/ denosumab.
Authors
- Eric J. Yeh (ORCID: https://orcid.org/0000-0002-9357-9626)
- Therese Aubry de Maraumont
- Luis Miguel Camacho Cordero
- Juan Pablo Díaz Martinez (ORCID: https://orcid.org/0009-0005-2836-699X)
- Elly Natty Sánchez
Institutions
- Amgen (United States) (US)
- University of Toronto (CA)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1371/journal.pone.0299673
- Citations
- 4
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 6.89
Funders
- Amgen